128 related articles for article (PubMed ID: 38401646)
21. Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized Trial.
Jardine MJ; Zhou Z; Mahaffey KW; Oshima M; Agarwal R; Bakris G; Bajaj HS; Bull S; Cannon CP; Charytan DM; de Zeeuw D; Di Tanna GL; Greene T; Heerspink HJL; Levin A; Neal B; Pollock C; Qiu R; Sun T; Wheeler DC; Zhang H; Zinman B; Rosenthal N; Perkovic V;
J Am Soc Nephrol; 2020 May; 31(5):1128-1139. PubMed ID: 32354987
[TBL] [Abstract][Full Text] [Related]
22. Affinity-Enhanced Multimeric VEGF (Vascular Endothelial Growth Factor) and PlGF (Placental Growth Factor) Variants for Specific Adsorption of sFlt-1 to Restore Angiogenic Balance in Preeclampsia.
Matin M; Mörgelin M; Stetefeld J; Schermer B; Brinkkoetter PT; Benzing T; Koch M; Hagmann H
Hypertension; 2020 Oct; 76(4):1176-1184. PubMed ID: 32623922
[TBL] [Abstract][Full Text] [Related]
23. Contrasting effects of chronic hypoxia and nitric oxide synthase inhibition on circulating angiogenic factors in a rat model of growth restriction.
Bahtiyar MO; Buhimschi C; Ravishankar V; Copel J; Norwitz E; Julien S; Guller S; Buhimschi IA
Am J Obstet Gynecol; 2007 Jan; 196(1):72.e1-6. PubMed ID: 17240241
[TBL] [Abstract][Full Text] [Related]
24. Soluble fms-like tyrosine kinase to placental growth factor ratio in different stages of early-onset fetal growth restriction and small for gestational age.
Garcia-Manau P; Mendoza M; Bonacina E; Garrido-Gimenez C; Fernandez-Oliva A; Zanini J; Catalan M; Tur H; Serrano B; Carreras E
Acta Obstet Gynecol Scand; 2021 Jan; 100(1):119-128. PubMed ID: 32860218
[TBL] [Abstract][Full Text] [Related]
25. Longitudinal assessment of angiogenic markers in prediction of adverse outcome in women with confirmed pre-eclampsia.
Binder J; Palmrich P; Kalafat E; Haberl C; Schirwani N; Pateisky P; Khalil A
Ultrasound Obstet Gynecol; 2023 Dec; 62(6):843-851. PubMed ID: 37265117
[TBL] [Abstract][Full Text] [Related]
26. Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study).
Mahaffey KW; Neal B; Perkovic V; de Zeeuw D; Fulcher G; Erondu N; Shaw W; Fabbrini E; Sun T; Li Q; Desai M; Matthews DR;
Circulation; 2018 Jan; 137(4):323-334. PubMed ID: 29133604
[TBL] [Abstract][Full Text] [Related]
27. Class effects of SGLT2 inhibitors on cardiorenal outcomes.
Kluger AY; Tecson KM; Lee AY; Lerma EV; Rangaswami J; Lepor NE; Cobble ME; McCullough PA
Cardiovasc Diabetol; 2019 Aug; 18(1):99. PubMed ID: 31382965
[TBL] [Abstract][Full Text] [Related]
28. Angiogenic Factors in Cord Blood of Preterm Infants Predicts Subsequently Developing Bronchopulmonary Dysplasia.
Yang WC; Chen CY; Chou HC; Hsieh WS; Tsao PN
Pediatr Neonatol; 2015 Dec; 56(6):382-5. PubMed ID: 25997993
[TBL] [Abstract][Full Text] [Related]
29. Prediction of adverse perinatal outcome by serum placental growth factor and soluble fms-like tyrosine kinase-1 in women undergoing induction of labor.
Fiolna M; Machuca M; Karampitsakos T; Akolekar R; Nicolaides KH
Ultrasound Obstet Gynecol; 2019 Nov; 54(5):604-608. PubMed ID: 31444934
[TBL] [Abstract][Full Text] [Related]
30. [Different effects of pravastatin on sFlt-1, PlGF and VEGF in different preeclampsia-like mouse models].
Xiang QQ; Yang Z; Huai J; Wang GJ
Zhonghua Fu Chan Ke Za Zhi; 2019 Sep; 54(9):601-607. PubMed ID: 31550776
[No Abstract] [Full Text] [Related]
31. Circulating angiogenic factors and HIV among pregnant women in Zambia: a nested case-control study.
Smithmyer ME; Mabula-Bwalya CM; Mwape H; Chipili G; Spelke BM; Kasaro MP; De Paris K; Vwalika B; Sebastião YV; Stringer JSA; Price JT
BMC Pregnancy Childbirth; 2021 Jul; 21(1):534. PubMed ID: 34320947
[TBL] [Abstract][Full Text] [Related]
32. A prospective study of angiogenic markers and postmenopausal breast cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial.
Falk RT; Staff AC; Bradwin G; Karumanchi SA; Troisi R
Cancer Causes Control; 2016 Aug; 27(8):1009-17. PubMed ID: 27357932
[TBL] [Abstract][Full Text] [Related]
33. Maternal placental growth factor and soluble fms-like tyrosine kinase-1 reference ranges in post-term pregnancies: A prospective observational study.
Mitlid-Mork B; Bowe S; Gran JM; Bolstad N; Berg JP; Redman CW; Staff AC; Sugulle M
PLoS One; 2020; 15(10):e0240473. PubMed ID: 33079955
[TBL] [Abstract][Full Text] [Related]
34. Soluble fms-like tyrosine kinase-1 to placental growth factor ratio: ruling out pre-eclampsia for up to 4 weeks and value of retesting.
Zeisler H; Llurba E; Chantraine FJ; Vatish M; Staff AC; Sennström M; Olovsson M; Brennecke SP; Stepan H; Allegranza D; Schoedl M; Grill S; Hund M; Verlohren S
Ultrasound Obstet Gynecol; 2019 Mar; 53(3):367-375. PubMed ID: 30014562
[TBL] [Abstract][Full Text] [Related]
35. Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials.
Perkovic V; de Zeeuw D; Mahaffey KW; Fulcher G; Erondu N; Shaw W; Barrett TD; Weidner-Wells M; Deng H; Matthews DR; Neal B
Lancet Diabetes Endocrinol; 2018 Sep; 6(9):691-704. PubMed ID: 29937267
[TBL] [Abstract][Full Text] [Related]
36. Effects of Canagliflozin in Patients with Baseline eGFR <30 ml/min per 1.73 m
Bakris G; Oshima M; Mahaffey KW; Agarwal R; Cannon CP; Capuano G; Charytan DM; de Zeeuw D; Edwards R; Greene T; Heerspink HJL; Levin A; Neal B; Oh R; Pollock C; Rosenthal N; Wheeler DC; Zhang H; Zinman B; Jardine MJ; Perkovic V
Clin J Am Soc Nephrol; 2020 Dec; 15(12):1705-1714. PubMed ID: 33214158
[TBL] [Abstract][Full Text] [Related]
37. Effect of SGLT2 Inhibitors on Stroke and Atrial Fibrillation in Diabetic Kidney Disease: Results From the CREDENCE Trial and Meta-Analysis.
Zhou Z; Jardine MJ; Li Q; Neuen BL; Cannon CP; de Zeeuw D; Edwards R; Levin A; Mahaffey KW; Perkovic V; Neal B; Lindley RI;
Stroke; 2021 May; 52(5):1545-1556. PubMed ID: 33874750
[TBL] [Abstract][Full Text] [Related]
38. Effects of the SGLT2 inhibitor canagliflozin on plasma biomarkers TNFR-1, TNFR-2 and KIM-1 in the CANVAS trial.
Sen T; Li J; Neuen BL; Neal B; Arnott C; Parikh CR; Coca SG; Perkovic V; Mahaffey KW; Yavin Y; Rosenthal N; Hansen MK; Heerspink HJL
Diabetologia; 2021 Oct; 64(10):2147-2158. PubMed ID: 34415356
[TBL] [Abstract][Full Text] [Related]
39. Circulating soluble fms-like tyrosine kinase-1 and placental growth factor from 10 to 40 weeks' pregnancy in normotensive women.
Wataganara T; Pratumvinit B; Lahfahroengron P; Pooliam J; Talungchit P; Leetheeragul J; Sukpanichnant S
J Perinat Med; 2017 Oct; 45(7):895-901. PubMed ID: 28665791
[TBL] [Abstract][Full Text] [Related]
40. Cardiovascular Effects of Canagliflozin in Relation to Renal Function and Albuminuria.
Sarraju A; Bakris G; Cannon CP; Cherney D; Damaraju CV; Figtree GA; Gogate J; Greene T; Heerspink HJL; Januzzi JL; Neal B; Jardine MJ; Blais J; Kosiborod M; Levin A; Lingvay I; Weir MR; Perkovic V; Mahaffey KW
J Am Coll Cardiol; 2022 Nov; 80(18):1721-1731. PubMed ID: 36302584
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
